Kepran-D Tablet is a combination medication containing Domperidone 10 mg and Pantoprazole 40 mg, formulated to manage gastrointestinal disorders characterized by acid reflux and delayed gastric emptying. Domperidone, a dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and alleviating symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The synergistic action of these two agents addresses both the motility and acid secretion components of upper gastrointestinal disorders, improving patient outcomes. Kepran-D is indicated for the treatment of symptomatic GERD, dyspepsia, and other acid-peptic diseases accompanied by delayed gastric emptying. It is generally well tolerated; however, patients should use it under medical supervision, especially those with cardiac conditions or electrolyte imbalances, due to potential side effects such as QT prolongation associated with Domperidone. Dosage and duration should be individualized based on clinical response and physician guidance.